01501nam a2200337   45000010005000000100015000051000041000201010008000612000183000692100083002522150018003352250044003533300349003976060022007466060035007686060013008036060021008166060029008376060022008666060014008886060008009026060028009106060021009387000022009597010023009817010029010047010025010337010025010587100069010838520011011527701  a9291681687  a20050111d2004       y0pory50      ba  aeng  aHepatitis C and injecting drug useeimpact, costs and policy optionsfEuropean Monitoring Centre for Drugs and Drug Addictionged. lit. Johannes Jager, Wien Limburg ... [et all.]  aLuxembourgcOffice for Official Publications of the European Communitiesd2004  a389 p.d24 cm  aEMCDDA - Scientific Monograph Seriesv7  aPart I - Natural history, treatment, quality of life, epidemiology and prevention. Part II - Models of hepatitis C, injecting drug use and policy options. Part III - Healthcare costs of drug-related hepatitis C infection. Part IV - Wider costs of drug use. Part V - Cost-effectiveness of needle and syringe programmes and methadone maintenance.  aSAÚDE PÚBLICA  aTRATAMENTO DE TOXICODEPENDENTE  aMETADONA  aCONSUMO DE DROGA  aPREVENÇÃO PRIMÁRIA  aPOLÍTICA SOCIAL  aHEPATITE   aHIV  aPROGRAMAS DE TRATAMENTO  aUNIÃO EUROPEIA  aJagerbJager4340  aLimburgbWien4340  aKretzschmarbMirjam4340  aPostmabMaarten4340  aWiessingbLucas4340  aEUROPEAN MONITORING CENTER FOR DRUGS AND DRUG ADDICTION - EMCDDA  jDRO227